Smoking Cessation After Non-STEMI
Benefits of Smoking Cessation
- The European Society of Cardiology guidelines state that smoking cessation reduces mortality by at least one-third in post-MI patients, making it more impactful than most pharmacological interventions, with a significant reduction in mortality rates compared to those who continue smoking 1, 2
- Stopping smoking is potentially the most effective of all secondary prevention measures after myocardial infarction, with observational studies showing that those who quit have mortality rates less than half that of those who continue smoking 3
- Cardiovascular benefits begin almost immediately, with blood carbon monoxide levels normalizing within hours to days, immediately improving oxygen delivery to tissues, and significant morbidity reductions occur within the first 6 months of cessation 4
Optimal Timing and Approach for Smoking Cessation
- The convalescent period after NSTEMI is ideal for smoking cessation counseling because patients have not smoked during the acute hospitalization phase, providing a head start on nicotine withdrawal, and momentum for lifestyle change is particularly strong at the time of diagnosing cardiovascular disease 1, 2, 4
- Firm and explicit advice to stop smoking completely is the most important factor in initiating cessation, and the "Five A's" approach should be used systematically: Ask about smoking status, Advise unequivocally to quit, Assess degree of addiction and readiness, Assist with cessation strategy, and Arrange follow-up 4, 5
Pharmacotherapy Options
- Nicotine replacement therapy (patch, gum, lozenge, inhaler) can be combined with other pharmacotherapy and has been demonstrated safe in acute coronary syndrome patients 1, 2
- Varenicline 1 mg twice daily for 12 weeks is first-line with superior efficacy compared to bupropion and nicotine replacement, and bupropion SR 150 mg twice daily for 7-12 weeks achieves 44.2% abstinence rates versus 19.6% with placebo 6